OXFORD, UNITED KINGDOM - 8 OCTOBER 2024. Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced that it will be presenting data on BPL-003, a novel synthetic intranasal formulation of mebufotenin (5-MeO-DMT) benzoate, in a poster presentation at the European College of Neuropsychopharmacology (ECNP) 2025 Congress in Amsterdam, The Netherlands.
Dr Chandni Hindocha, Associate Director, Clinical Development at Beckley Psytech, will present a poster titled ‘The efficacy of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) on anhedonia in patients with treatment resistant depression: a Phase 2a open label study’ on Sunday 12th October at 12.35pm - 14.00pm CEST. The poster will show that a single 10 mg dose of intranasal BPL-003 may lead to clinically meaningful improvements in anhedonia and functional outcomes in individuals with treatment-resistant depression (TRD) that were sustained for up to 3 months.
The findings come from a Phase 2a open-label study of BPL-003 in patients with moderate-to-severe TRD who were not taking concurrent antidepressant treatment. Topline efficacy results from the study were shared in March 2024 and showed that a single 10mg dose of BPL-003 produced a rapid and durable antidepressant response that lasted for up to 3 months. 55% of patients met the criteria for remission from depression the day after dosing and this antidepressant effect was durable, with 55% of patients meeting the criteria for remission at day 29 and 45% meeting the criteria for remission at day 85.
Anhedonia is defined as a diminished capacity to experience or anticipate pleasure, and is estimated to affect up to 75% of people with major depressive disorder (MDD). It is associated with poorer disease prognosis, lower quality of life, increased severity and duration of depressive episodes and suboptimal response to treatment, including to some conventional antidepressants such as SSRI. In the study, anhedonia was measured with the Snaith Hamilton Pleasure Scale (SHAPS), a self-reported tool assessing consummatory pleasure, and the Montgomery-Åsberg Rating Scale (MADRS) scale Anhedonia Factor. The Sheehan Disability Scale (SDS) was also used to assess functional outcome.
Speaking on Beckley Psytech’s attendance at ECNP, Dr Chandni Hindocha says: “We are delighted to share these findings at ECNP, one of the most important forums for advancing neuroscience and mental health research. Presenting these results is an exciting opportunity to further scientific research and highlight the potential of BPL-003 to produce both symptomatic and functional improvements in those with TRD.”
For more information please contact: Charlotte Chorley, Communications Lead, at info@beckleypsytech.com
About Beckley Psytech
Beckley Psytech Ltd is a private biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing rapid-acting psychedelic medicines. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, Beckley Psytech combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden these conditions have on individuals, healthcare systems and society. For more information about Beckley Psytech, visit www.beckleypsytech.com or follow the Company on LinkedIn.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
%20(1).jpg)
%20(1).jpg)
